The evolving genomic classification of lung cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
EGFR gene mutations and ALK gene fusions are well‐characterized molecular targets in NSCLC. Activating alterations in a variety of potential oncogenic driver genes have also been identified in NSCLC, including ROS1, RET, MET, HER2, and BRAF. Together with EGFR and ALK, these mutations account for ∼20% of NSCLCs. The identification of these oncogenic drivers has led to the design of rationally targeted therapies that have produced superior clinical outcomes in tumours harbouring these mutations. Many patients, however, have de novo or acquired resistance to these therapies. In addition, most NSCLCs are genetically complex tumours harbouring multiple potential activating events. For these patients, disease subsets are likely to be defined by combination strategies involving a number of targeted agents. These targets include FGFR1, PTEN, MET, MEK, PD‐1/PD‐L1, and NaPi2b. In light of the myriad new biomarkers and targeted agents, multiplex testing strategies will be invaluable in identifying the appropriate patients for each therapy and enabling targeted agents to be channelled to the patients most likely to gain benefit. The challenge now is how best to interpret the results of these genomic tests, in the context of other clinical data, to optimize treatment choices in NSCLC. © 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · cited 1×
“In prospective phase III trials, patients with previously untreated EGFR mutation-positive NSCLC achieved significantly longer progression-free survival (PFS) with the reversible EGFR tyrosine-kinase inhibitors (TKIs) erlotinib and gefitinib than with platinum-doublet chemotherapy [8,12,14].”
BackgroundIdentification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 3×
“The French National Cancer Institute, in collaboration with the French Ministry of Health, recently introduced a programme of free molecular diagnostic testing for all patients with solid tumours, which includes testing for EGFR mutations and EML4–ALK rearrangements in lung cancer [86].”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · cited 1×
“In prospective phase III trials, patients with previously untreated EGFR mutation-positive NSCLC achieved significantly longer progression-free survival (PFS) with the reversible EGFR tyrosine-kinase inhibitors (TKIs) erlotinib and gefitinib than with platinum-doublet chemotherapy [8,12,14].”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 1×
“In the subsequent phase III trial, secondline crizotinib demonstrated superior PFS and response rates to chemotherapy alone in patients with locally advanced or metastatic ALK -positive NSCLC [13].”
BackgroundShigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation
Cited by
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
Cheng, T.-Y. D., Cramb, S. M., Baade, P. D., Youlden, D. R., Nwogu, C., & Reid, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.021 · Cited by 600
Kowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M., Schmid, P., Kadel, E. E., Wistuba, I., Chaft, J., Rizvi, N. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802166115 · Cited by 235
“To confirm that the observed differential expression of EMT signature was not due to potential differences in TC content, the expression of TTF1 (for nonsquamous NSCLC tumors) and p63 (for squamous NSCLC tumors) (15, 16) was evaluated and found to be similar between the TC3 and IC3 subgroups (SI Appendix, Fig.”
ResultSelf-citationAn Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Girard, L., Rodriguez-Canales, J., Behrens, C., Thompson, D. M., Botros, I. W., Tang, H., Xie, Y., Rekhtman, N., Travis, W. D., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2900 · Cited by 154
Self-citationsnoRNAs offer novel insight and promising perspectives for lung Cancer understanding and management
Mourksi, N.-E.-H., Morin, C., Fenouil, T., Diaz, J.-J., & Marcel, V. (2020) · Cells · doi:10.3390/cells9030541 · Cited by 62
Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Wang, Y., & You, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19831 · Cited by 38
“They may represent up to 30% of lung cancer in the Caucasian smoking population [4], with 80% of them are specifically altered in codon12 [5].”
Background
Metadata
- Authors
- Shames, D. S., & Wistuba, I. I.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2013-12-10
- Volume
- 232
- Issue
- 2
- Pages
- 121-133
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1676117227
- Cited by
- 98
- References
- 22
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolving genomic classification of lung cancer. https://app.cochat.ai/papers/10.1002/path.4275
- The paper
- Shames, D. S., & Wistuba, I. I. (2014). The evolving genomic classification of lung cancer. The Journal of Pathology. https://doi.org/10.1002/path.4275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.